See more : Northbaze Group AB (publ) (NBZ.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Amarin Corporation plc (AMRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amarin Corporation plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Kimball Electronics, Inc. (KE) Income Statement Analysis – Financial Results
- Chemomab Therapeutics Ltd. (CMMB) Income Statement Analysis – Financial Results
- PCL Technologies, Inc. (4977.TW) Income Statement Analysis – Financial Results
- Rathbones Group Plc (RAT.L) Income Statement Analysis – Financial Results
- Samty Co., Ltd. (3244.T) Income Statement Analysis – Financial Results
Amarin Corporation plc (AMRN)
About Amarin Corporation plc
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 306.91M | 369.19M | 583.19M | 614.06M | 429.76M | 229.21M | 181.10M | 130.08M | 81.76M | 54.20M | 26.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.37M | 500.00K | 500.00K | 1.02M | 7.37M | 65.51M | 53.77M | 17.55M | 11.22M | 19.00M | 24.30M | 21.50M | 29.10M | 18.70M | 14.70M |
| Cost of Revenue | 141.37M | 126.71M | 121.33M | 131.44M | 96.02M | 54.54M | 44.95M | 34.36M | 27.88M | 20.49M | 11.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 107.00K | 11.91M | 30.13M | 21.46M | 5.22M | 2.98M | 3.70M | 2.80M | 4.00M | 4.90M | 0.00 | 3.10M |
| Gross Profit | 165.54M | 242.48M | 461.86M | 482.62M | 333.74M | 174.67M | 136.15M | 95.72M | 53.88M | 33.72M | 14.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.37M | 500.00K | 500.00K | 910.00K | -4.55M | 35.38M | 32.32M | 12.33M | 8.24M | 15.30M | 21.50M | 17.50M | 24.20M | 18.70M | 11.60M |
| Gross Profit Ratio | 53.94% | 65.68% | 79.20% | 78.59% | 77.66% | 76.20% | 75.18% | 73.58% | 65.90% | 62.21% | 54.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 89.48% | -61.74% | 54.01% | 60.10% | 70.25% | 73.47% | 80.53% | 88.48% | 81.40% | 83.16% | 100.00% | 78.91% |
| Research & Development | 22.22M | 30.41M | 29.31M | 38.96M | 34.39M | 55.90M | 47.16M | 49.98M | 51.06M | 50.33M | 72.75M | 58.96M | 21.60M | 28.01M | 17.84M | 12.95M | 12.11M | 17.19M | 8.31M | 3.48M | 5.44M | 6.22M | 4.14M | 5.75M | 7.44M | 19.80M | 19.80M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 88.61M | 118.80M | 141.86M | 112.66M | 323.62M | 180.18M | 112.04M | 93.40M | 93.07M | 79.35M | 121.25M | 57.79M | 22.56M | 17.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 111.33M | 185.61M | 266.47M | 350.65M | 0.00 | 46.82M | 22.51M | 17.97M | 7.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 199.94M | 304.42M | 408.33M | 463.31M | 323.62M | 227.00M | 134.55M | 111.37M | 101.04M | 79.35M | 121.25M | 57.79M | 22.56M | 17.09M | 15.25M | 15.23M | 19.46M | 13.27M | 9.77M | 9.03M | 30.89M | 23.66M | 33.26M | 9.14M | 5.30M | 9.70M | 7.30M | 34.60M | 18.60M | 0.00 | 9.90M |
| Other Expenses | 10.97M | -740.00K | -302.00K | 104.00K | -75.00K | -326.00K | 74.00K | -482.00K | -228.00K | 3.73M | -1.19M | -427.00K | 0.00 | 0.00 | -2.16M | 0.00 | 9.17M | 674.00K | 676.00K | -510.00K | -2.05M | 39.24M | 0.00 | -1.00K | 2.32M | 2.60M | 2.50M | 1.20M | 1.00M | 0.00 | 600.00K |
| Operating Expenses | 233.13M | 334.83M | 437.64M | 502.27M | 358.02M | 282.90M | 181.71M | 161.35M | 152.10M | 129.67M | 194.00M | 116.75M | 44.16M | 45.10M | 30.93M | 28.18M | 40.73M | 31.13M | 18.76M | 12.00M | 34.27M | 69.12M | 37.40M | 14.89M | 15.05M | 32.10M | 29.60M | 35.80M | 19.60M | 0.00 | 10.50M |
| Cost & Expenses | 374.50M | 461.54M | 558.97M | 633.72M | 454.03M | 337.44M | 226.66M | 195.71M | 179.98M | 150.16M | 205.91M | 116.75M | 44.16M | 45.10M | 30.93M | 28.18M | 40.73M | 31.13M | 18.76M | 12.11M | 46.19M | 99.25M | 58.85M | 20.11M | 18.03M | 35.80M | 32.40M | 39.80M | 24.50M | 0.00 | 13.60M |
| Interest Income | 11.86M | 2.82M | 1.22M | 4.90M | 8.50M | 1.07M | 429.00K | 234.00K | 132.00K | 96.00K | 343.00K | 544.00K | 231.00K | 53.00K | 780.00K | 9.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.00K | 15.00K | 129.00K | 2.61M | 6.63M | 7.80M | 9.77M | 18.44M | 20.05M | 18.48M | 34.18M | 18.09M | 1.00K | 19.00K | 8.23M | 2.14M | 6.46M | 0.00 | 1.80M | 0.00 | 0.00 | 29.46M | 0.00 | 0.00 | 0.00 | 24.40M | 800.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.97M | 3.09M | 2.86M | 2.05M | 862.56K | 667.87K | 715.59K | 777.59K | 812.00K | 844.00K | 892.00K | 449.00K | 76.00K | 63.00K | 582.00K | 251.00K | 386.00K | 795.00K | 810.00K | 754.00K | 671.00K | 8.29M | 21.22M | 2.42M | 2.32M | 2.60M | 2.50M | 1.20M | 1.00M | 0.00 | 600.00K |
| EBITDA | -50.90M | -100.65M | 14.28M | -12.71M | -15.06M | -106.63M | -44.82M | -56.53M | -97.41M | -39.78M | -134.62M | -152.32M | -66.79M | -249.90M | -55.16M | -19.87M | -38.44M | -31.16M | -19.29M | -9.85M | -6.09M | -25.45M | 16.14M | -224.00K | -4.81M | -7.90M | -5.60M | -17.10M | 5.60M | 18.70M | 1.70M |
| EBITDA Ratio | -16.59% | -24.45% | 4.31% | -2.39% | -3.69% | -47.36% | -24.49% | -50.82% | -120.42% | -170.16% | -681.23% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -437.07% | -6,280.80% | -3,358.80% | -3,309.93% | -732.53% | 6.42% | 29.96% | -2.85% | -27.11% | -8.95% | -15.64% | -87.44% | 16.15% | 100.00% | 9.52% |
| Operating Income | -67.59M | -92.34M | 22.28M | -19.66M | -24.28M | -108.23M | -45.56M | -65.63M | -98.22M | -95.96M | -182.11M | -116.75M | -44.16M | -45.10M | -52.30M | -28.18M | -40.73M | -31.16M | -18.91M | -11.09M | -38.82M | -32.66M | -5.08M | -2.56M | -6.81M | -16.80M | -8.10M | -18.30M | 4.60M | 18.70M | 1.10M |
| Operating Income Ratio | -22.02% | -25.01% | 3.82% | -3.20% | -5.65% | -47.22% | -25.15% | -50.45% | -120.14% | -177.03% | -691.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -553.06% | -6,232.20% | -3,781.60% | -1,090.66% | -527.10% | -49.86% | -9.44% | -14.59% | -60.71% | -88.42% | -33.33% | -85.12% | 15.81% | 100.00% | 7.48% |
| Total Other Income/Expenses | 13.92M | 2.06M | 789.00K | 2.40M | 1.80M | -8.12M | -9.26M | -10.76M | -20.07M | 36.75M | 12.69M | -54.20M | -22.73M | -204.92M | -29.36M | 7.22M | -7.08M | 3.64M | -2.35M | 222.00K | 12.24M | -883.00K | -298.00K | 525.00K | -1.63M | -5.50M | -3.20M | 1.60M | 900.00K | 0.00 | 200.00K |
| Income Before Tax | -53.67M | -103.81M | 11.29M | -17.26M | -22.48M | -116.35M | -54.82M | -76.38M | -118.29M | -59.20M | -169.42M | -170.07M | -66.61M | -250.09M | -59.76M | -20.70M | -39.03M | -27.72M | -19.41M | 11.35M | -26.58M | -33.55M | -4.71M | -2.22M | -10.15M | -30.10M | -11.30M | -16.70M | 5.50M | 0.00 | 1.30M |
| Income Before Tax Ratio | -17.49% | -28.12% | 1.94% | -2.81% | -5.23% | -50.76% | -30.27% | -58.72% | -144.69% | -109.22% | -642.94% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -529.99% | -5,543.80% | -3,881.00% | 1,115.54% | -360.90% | -51.21% | -8.76% | -12.66% | -90.48% | -158.42% | -46.50% | -77.67% | 18.90% | 0.00% | 8.84% |
| Income Tax Expense | 5.44M | 2.00M | 3.56M | 745.00K | 164.00K | 96.00K | 13.05M | 9.97M | -3.09M | -2.84M | -3.19M | 9.12M | 2.52M | -501.00K | -440.00K | -674.00K | -837.00K | -799.00K | -698.00K | 7.33M | -7.36M | 3.54M | 412.00K | 342.00K | -27.00K | 100.00K | 600.00K | -1.10M | 1.40M | 15.90M | 500.00K |
| Net Income | -59.11M | -105.80M | 7.73M | -18.00M | -22.65M | -116.45M | -67.87M | -86.35M | -115.20M | -56.36M | -166.23M | -179.18M | -69.13M | -249.59M | -59.32M | -20.02M | -38.20M | -26.92M | -18.71M | 4.01M | -19.22M | -37.08M | -4.76M | 2.36M | 4.37M | -28.80M | -7.70M | -15.60M | 4.10M | 2.80M | 900.00K |
| Net Income Ratio | -19.26% | -28.66% | 1.33% | -2.93% | -5.27% | -50.80% | -37.47% | -66.38% | -140.91% | -103.99% | -630.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -518.63% | -5,384.00% | -3,741.40% | 394.49% | -261.02% | -56.61% | -8.85% | 13.43% | 38.96% | -151.58% | -31.69% | -72.56% | 14.09% | 14.97% | 6.12% |
| EPS | -0.15 | -0.26 | 0.02 | -0.05 | -0.07 | -0.39 | -0.25 | -0.41 | -0.64 | -0.32 | -1.03 | -1.24 | -0.53 | -2.49 | -1.40 | -0.91 | -4.08 | -3.35 | -4.63 | 1.72 | -11.24 | -39.71 | -0.67 | 6.42 | 2.90 | -19.29 | -52.00 | -110.00 | 31.00 | 20.00 | 8.00 |
| EPS Diluted | -0.15 | -0.26 | 0.02 | -0.05 | -0.07 | -0.39 | -0.25 | -0.41 | -0.64 | -0.32 | -0.99 | -1.24 | -0.53 | -2.49 | -1.40 | -0.91 | -4.08 | -3.35 | -4.63 | 1.72 | -11.24 | -39.71 | -0.40 | 3.02 | 2.90 | -19.29 | -52.00 | -110.00 | 31.00 | 20.00 | 8.00 |
| Weighted Avg Shares Out | 407.66M | 401.16M | 395.99M | 381.76M | 342.54M | 297.24M | 270.65M | 210.61M | 179.59M | 173.72M | 161.02M | 144.02M | 130.25M | 100.24M | 42.42M | 22.06M | 9.37M | 8.03M | 4.04M | 1.79M | 1.71M | 933.77K | 7.12M | 149.89K | 1.50M | 1.49M | 148.08K | 141.82K | 132.26K | 140.00K | 112.50K |
| Weighted Avg Shares Out (Dil) | 407.66M | 401.16M | 402.48M | 381.76M | 342.54M | 297.24M | 270.65M | 211.87M | 180.65M | 173.82M | 167.07M | 144.02M | 130.25M | 100.24M | 42.42M | 22.06M | 9.37M | 8.03M | 4.04M | 1.79M | 1.71M | 933.77K | 12.04M | 842.09K | 1.50M | 1.49M | 148.08K | 141.82K | 132.26K | 140.00K | 112.50K |
Amarin Reports Second Quarter 2023 Financial Results
-- Company Reported Total Net Revenues of $80 Million in Second Quarter 2023; Total Net Revenues Included Net Product Revenues of $65 Million, $15 Million in License and Royalty Revenues, of Which $11 Million is Non-Cash -- -- Delivered Positive...
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
Collaboration Broadens Reach of VAZKEPA to Additional Ten Countries Leveraging Lotus' Established Commercial and Marketing Expertise in the Region Collaboration Broadens Reach of VAZKEPA to Additional Ten Countries Leveraging Lotus' Established Commercial and Marketing Expertise in the Region
Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress
DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the acceptance of funded research for presentation at the European Society of Cardiology (ESC) Congress, both onsite and online in Amsterdam, August 25-28,...
Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain
-- Spain's Drug Pricing Committee recommends reimbursement of VAZKEPA® (icosapent ethyl) to reduce the risk of cardiovascular (CV) events in patients with high cardiovascular risk 1 -- -- Positive recommendation marks the final step in the reimbursement process in Spain...
Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt
– Agreement Underscores Board's Commitment to Aligning Executive Compensation with Shareholder Returns –
Amarin (AMRN) Dips 16% on Layoff Plan & Preliminary Sales Miss
Amarin (AMRN) decides to initiate a restructuring plan to maximize cash flow opportunities in the United States. It also reports preliminary product revenues of around $65 million in Q2.
Amarin Appoints Patrick Holt as President and Chief Executive Officer
DUBLIN, Ireland and BRIDGEWATER, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that the Company's Board of Directors has appointed Patrick Holt as President and Chief Executive Officer and as a member of the...
Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally
-- Focus on Gaining Access for European Patients in Remaining Geographies and Strategic Use of Commercial Resources -- -- Maximizes Cash Flow Opportunity Through Streamlined Model in U.S. --
Amarin: New Management, But No Radical Changes To Strategy, Or Outlook
Amarin recently acquired a completely revamped management. There seems to be no radical shift in strategy, however. Therefore, there is no radical change in my negative opinion on the outlook.
Amarin Corporation plc (AMRN) Presents at Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)
Start Time: 17:40 January 1, 0000 6:14 PM ET Amarin Corporation plc (NASDAQ:AMRN ) Goldman Sachs 44th Annual Global Healthcare Conference June 12, 2023, 17:40 PM ET Company Participants Aaron Berg - Interim President and CEO Tom Reilly - CFO...
Source: https://incomestatements.info
Category: Stock Reports